Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 12, 2024

BUY
$161.01 - $317.85 $27 Million - $53.2 Million
167,448 Added 2482.55%
174,193 $55.1 Million
Q3 2023

Oct 13, 2023

BUY
$164.66 - $218.08 $951,570 - $1.26 Million
5,779 Added 598.24%
6,745 $1.14 Million
Q2 2023

Jul 10, 2023

SELL
$176.32 - $240.22 $1.39 Million - $1.89 Million
-7,862 Reduced 89.06%
966 $209,000
Q1 2023

Apr 28, 2023

BUY
$161.33 - $204.36 $197,951 - $250,749
1,227 Added 16.14%
8,828 $1.6 Million
Q4 2022

Feb 02, 2023

BUY
$191.53 - $236.82 $92,508 - $114,384
483 Added 6.79%
7,601 $1.49 Million
Q3 2022

Oct 31, 2022

SELL
$123.79 - $277.42 $1.62 Million - $3.62 Million
-13,054 Reduced 64.71%
7,118 $1.6 Million
Q2 2022

Jul 29, 2022

BUY
$93.97 - $143.33 $1.11 Million - $1.69 Million
11,785 Added 140.52%
20,172 $2.55 Million
Q1 2022

Apr 29, 2022

SELL
$98.9 - $132.37 $251,008 - $335,955
-2,538 Reduced 23.23%
8,387 $1.06 Million
Q4 2021

Feb 07, 2022

BUY
$110.64 - $159.4 $530,629 - $764,482
4,796 Added 78.25%
10,925 $1.43 Million
Q3 2021

Nov 01, 2021

BUY
$101.2 - $125.87 $283,461 - $352,561
2,801 Added 84.16%
6,129 $750,000
Q2 2021

Aug 12, 2021

SELL
$107.45 - $135.95 $231,554 - $292,972
-2,155 Reduced 39.3%
3,328 $379,000
Q1 2021

May 13, 2021

SELL
$95.46 - $133.08 $4.49 Million - $6.26 Million
-47,062 Reduced 89.57%
5,483 $659,000
Q4 2020

Feb 04, 2021

BUY
$75.23 - $109.23 $1.51 Million - $2.19 Million
20,046 Added 61.68%
52,545 $5.34 Million
Q3 2020

Nov 09, 2020

BUY
$71.31 - $109.74 $1.72 Million - $2.65 Million
24,148 Added 289.16%
32,499 $2.51 Million
Q2 2020

Jul 20, 2020

BUY
$62.14 - $117.21 $273,353 - $515,606
4,399 Added 111.31%
8,351 $931,000
Q1 2020

Apr 30, 2020

BUY
$60.41 - $115.92 $238,740 - $458,115
3,952 New
3,952 $285,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.